However, most of these studies reported no or low efficacy when used as monotherapy, while combination of CSF1R inhibition with standard of care (e.g., chemotherapy or irradiation) led to synergistic anti-tumor effects in, e.g., glioma and breast cancer (132, 133). This evidence concerns the gene CSF1R and breast cancer.